Expanded Use of Cannabidiol Oral Solution
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Sponsor: MultiCare Health System Research Institute
Listed as NCT03196934, this observational or N/A phase trial focuses on Refractory Epilepsy and remains ongoing. Sponsored by MultiCare Health System Research Institute, it has been updated 8 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2024 — Jul 2024 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Jan 2021 — Mar 2024 [monthly]
Available
-
Jan 2020 — Jan 2021 [monthly]
Available
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2020 [monthly]
Available
-
Apr 2018 — Jun 2018 [monthly]
Available
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MultiCare Health System Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.